rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

LB Pharmaceuticals Inc

LBRX · Nasdaq

Health CareBiotechnologyJust started moving

LBRX stood above a rising 150-day average in 23 of the last 23 weekly readings, every one of them. It is 12.0% above that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Just started moving
Weeks in an uptrend
23 in a row
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
112 (+37)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 23 of 23 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$72.3MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0
WhoDidSharesTraded
Deep Track Biotechnology Master Fund, Ltd.10% ownerbought286,205at $34.9430 Jul 2026filed 3 Aug 2026
Deep Track Biotechnology Master Fund, Ltd.10% ownerbought378,444at $21.176 Feb 2026filed 10 Feb 2026
Deep Track Biotechnology Master Fund, Ltd.10% ownerbought93,925at $21.176 Feb 2026filed 10 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders112+37 on the quarter
New · exited43 · 5
Reported value$970.1M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Deep Track Capital, LPunchanged · filed 14 Aug 20263,352,804$108.8M00.0%
BlackRock, Inc.added · filed 7 Aug 20262,734,305$88.7M+263,460+10.7%
RA CAPITAL MANAGEMENT, L.P.unchanged · filed 14 Aug 20262,208,604$71.7M00.0%
Trails Edge Capital Partners, LPadded · filed 14 Aug 20261,523,022$49.4M+203,660+15.4%
Commodore Capital LPunchanged · filed 14 Aug 20261,500,000$48.7M00.0%
JPMORGAN CHASE & COnew · filed 12 Aug 20261,497,293$48.9M+1,497,293
TCG Crossover Management, LLCreduced · filed 14 Aug 20261,447,310$47.0M-392,179−21.3%
Caligan Partners LPunchanged · filed 14 Aug 20261,438,070$46.7M00.0%
Spruce Street Capital LPunchanged · filed 13 Aug 20261,376,159$44.7M00.0%
Nantahala Capital Management, LLCunchanged · filed 14 Aug 20261,052,894$34.2M00.0%
30 Sep 2025 – 30 Jun 2026
5382110Sep 25Dec 25Mar 26Jun 26

Everyone who traded it

Joseph M. Miller Company insiderChief Financial Officer · last 9 Oct 20260 · 0
Susan Gani Kozauer Company insiderChief Medical Officer · last 9 Oct 20260 · 0
David Kroin Company insider10% owner · last 30 Jul 20260 · 0
Deep Track Biotechnology Master Fund, Ltd. Company insider10% owner · last 30 Jul 20260 · 0
J. Scott Garland Company insiderDirector · last 3 Jun 20260 · 0
Ran Nussbaum Company insiderDirector · last 3 Jun 20261 · 0
Rebecca Luse Company insiderDirector · last 3 Jun 20260 · 0
Rekha Hemrajani Company insiderDirector · last 3 Jun 20260 · 0
Robert A. Lenz Company insiderDirector · last 3 Jun 20260 · 0
Robert R. Ruffolo Company insiderDirector · last 3 Jun 20260 · 0
William P. Kane Jr. Company insiderDirector · last 3 Jun 20260 · 0
Panandiker Kaya Kamlesh Pai Company insiderChief Commercial Officer · last 10 Dec 20250 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 23 Mar 202613.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$250.2M
Free cash flowFY 2025 · to 31 Dec 2025−$35.3M

Analyst forecasts

No analyst forecasts yet.